drugset

drugset / Trial / NCT05064397

A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)

NCT05064397 ↗

Phase 3 Completed 131 enrolled H. Lundbeck A/S

NaSingle-groupOpen-labelTreatment

Summary

The main goal of this trial is to inform about long-term safety and tolerability of eptinezumab in participants with chronic cluster headache.

Timeline

Start: 2021-09-17
Primary completion: 2023-06-29
Completion: 2023-06-29

Publications

Tassorelli C, Jensen RH, Goadsby PJ, Charles AC, Tepper SJ, Snoer AH, Josiassen MK, Linander CB, Ettrup A, Sperling B, Boneva N. Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial. Lancet Neurol. 2025 May;24(5):429-440. doi: 10.1016/S1474-4422(25)00065-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eptinezumab	Monoclonal antibody	400 mg	Intravenous

Indications